Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study

Details

Ressource 1Download: serval:BIB_E584D58FCD72.P001 (168.46 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_E584D58FCD72
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
Journal
Clinical Infectious Diseases
Author(s)
Ledergerber  B., Furrer  H., Rickenbach  M., Lehmann  R., Elzi  L., Hirschel  B., Cavassini  M., Bernasconi  E., Schmid  P., Egger  M., Weber  R.
ISSN
1537-6591 (Electronic)
Publication state
Published
Issued date
07/2007
Volume
45
Number
1
Pages
111-9
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jul 1
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment. METHODS: We studied associations of new-onset diabetes mellitus with hepatitis B virus and hepatitis C virus coinfections and antiretroviral therapy in participants in the Swiss HIV Cohort Study, using Poisson regression. RESULTS: A total of 123 of 6513 persons experienced diabetes mellitus during 27,798 person-years of follow-up (PYFU), resulting in an incidence of 4.4 cases per 1000 PYFU (95% confidence interval [CI], 3.7-5.3 cases per 1000 PYFU). An increased incidence rate ratio (IRR) was found for male subjects (IRR, 2.5; 95% CI, 1.5-4.2), older age (IRR for subjects >60 years old, 4.3; 95% CI, 2.3-8.2), black (IRR, 2.1; 95% CI, 1.1-4.0) and Asian (IRR, 4.9; 95% CI, 2.2-10.9) ethnicity, Centers for Disease Control and Prevention disease stage C (IRR, 1.6; 95% CI, 1.04-2.4), and obesity (IRR, 4.7; 95% CI, 3.1-7.0), but results for hepatitis C virus infection or active hepatitis B virus infection were inconclusive. Strong associations were found for current treatment with nucleoside reverse-transcriptase inhibitors (IRR, 2.22; 95% CI, 1.11-4.45), nucleoside reverse-transcriptase inhibitors plus protease inhibitors (IRR, 2.48; 95% CI, 1.42-4.31), and nucleoside reverse-transcriptase inhibitors plus protease inhibitors and nonnucleoside reverse-transcriptase inhibitors (IRR, 3.25; 95% CI, 1.59-6.67) but were not found for treatment with nucleoside reverse-transcriptase inhibitors plus nonnucleoside reverse-transcriptase inhibitors (IRR, 1.47; 95% CI, 0.77-2.82). CONCLUSIONS: In addition to traditional risk factors, current treatment with protease inhibitor- and nucleoside reverse-transcriptase inhibitor-containing regimens was associated with the risk of developing type 2 diabetes mellitus. Our study did not find a significant association between viral hepatitis infection and risk of incident diabetes.
Keywords
Adult Anti-HIV Agents/therapeutic use Antiretroviral Therapy, Highly Active Cohort Studies Diabetes Mellitus, Type 2/*epidemiology/etiology Female HIV Infections/*complications/drug therapy Humans Incidence Male Middle Aged Risk Factors Sweden/epidemiology
Pubmed
Web of science
Open Access
Yes
Create date
29/01/2008 8:52
Last modification date
25/09/2019 6:11
Usage data